Acrivon Therapeutics, Common Stock Fundamentals
| ACRV Stock | 7.16 0.61 9.31% |
Acrivon Therapeutics, Common fundamentals help investors to digest information that contributes to Acrivon Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Acrivon Stock. The fundamental analysis module provides a way to measure Acrivon Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acrivon Therapeutics, stock.
At this time, Acrivon Therapeutics,'s Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to climb to about 70.6 M in 2024, whereas Gross Profit is likely to drop (562.8 K) in 2024. Acrivon | Select Account or Indicator |
Acrivon Therapeutics, Common Company Shares Owned By Insiders Analysis
Acrivon Therapeutics,'s Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Acrivon Therapeutics, Shares Owned By Insiders | 22.38 % |
Most of Acrivon Therapeutics,'s fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acrivon Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 22.38% of Acrivon Therapeutics, Common are shares owned by insiders. This is 47.43% higher than that of the Biotechnology sector and 57.83% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 121.8% lower than that of the firm.
Acrivon Therapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acrivon Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Acrivon Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acrivon Therapeutics, competition to find correlations between indicators driving Acrivon Therapeutics,'s intrinsic value. More Info.Acrivon Therapeutics, Common is number one stock in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Acrivon Therapeutics,'s Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Acrivon Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Acrivon Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acrivon Therapeutics,'s direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acrivon Therapeutics, could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics, by comparing valuation metrics of similar companies.Acrivon Therapeutics, is currently under evaluation in shares owned by insiders category among its peers.
Acrivon Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Acrivon Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Acrivon Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Acrivon Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 20.5 M | ||||
| Shares Outstanding | 31.14 M | ||||
| Shares Owned By Insiders | 22.38 % | ||||
| Shares Owned By Institutions | 75.97 % | ||||
| Number Of Shares Shorted | 1.08 M | ||||
| Price To Book | 1.04 X | ||||
| EBITDA | (59.85 M) | ||||
| Net Income | (60.39 M) | ||||
| Total Debt | 4.64 M | ||||
| Book Value Per Share | 5.38 X | ||||
| Cash Flow From Operations | (42.64 M) | ||||
| Short Ratio | 15.38 X | ||||
| Earnings Per Share | (2.66) X | ||||
| Target Price | 21.56 | ||||
| Number Of Employees | 58 | ||||
| Market Capitalization | 203.94 M | ||||
| Total Asset | 138.26 M | ||||
| Retained Earnings | (116.42 M) | ||||
| Working Capital | 116.39 M | ||||
| Net Asset | 138.26 M |
About Acrivon Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acrivon Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 79.3 K | 74.2 K | |
| Cost Of Revenue | 536 K | 680.9 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.